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Introduction 
Consideration of the possibility that T lympho- 
cytes might be central to the pathogenesis of rheumatoid 
arthritis (RA) first became prominent in the 1980s (1). 
Only after new approaches became available for under- 
standing the physiology of the T lymphocyte, particularly 
the generation of monoclonal antibodies that identified 
the function of important T cell surface structures, was 
there the development of a hypothesis for the etiology 
and pathogenesis of RA that placed the T cell at the 
center of this disease. By the end of the 1980s a 
substantial body of evidence had accumulated that jus- 
tified construction of a “T cell paradigm” for RA, and 
this model has formed the basis for trials of biologic 
therapies and other novel immunotherapies in the treat- 
ment of this disease. 
Observations used to support the concept of a 
central role of T cells in RA are listed in Table 1. Some 
are undisputed facts, which any comprehensive explana- 
tion for the pathogenesis of the disease must take into 
account. These include the abundance of T lymphocytes 
in the joint, the distinctive profile of surface markers on 
synovial T cells compared with peripheral blood, and the 
increased frequency of specific class I1 major histocom- 
patibility complex (MHC) alleles in RA. Other observa- 
tions listed in Table 1, however, are more controversial. 
The important role of T cells in animal models of 
inflammatory arthritis is of significance only insofar as 
such models are accurate representations of RA, which 
remains unproven. Improvement in RA with T cell- 
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directed therapeutic approaches would perhaps have 
been accepted as a well-demonstrated fact 10 years ago, 
but has been increasingly doubted due to more recent 
data. Whether the T cell repertoire in RA displays a 
reproducible pattern of oligoclonality and whether syno- 
vial T cell responses to identifiable antigens are impor- 
tant in RA remain points of confusion and controversy. 
On these issues the available data may as easily provide 
evidence against a role for T cells as they do in favor of 
such a role. 
Table 2 summarizes key aspects of the current 
evidence against the importance of T cells in RA. It is of 
course difficult to prove that a specific autoantigen 
causes a human autoimmune disease, but in RA (unlike 
certain other human autoimmune conditions such as 
myasthenia gravis, autoimmune thyroid disease, and 
multiple sclerosis), strong evidence for the importance 
of any specific autoantigen is not yet available. In the 
absence of an autoantigen, attempts to identify oligo- 
clonality and specificity in RA T cell populations have 
not yielded clear answers that illuminate disease patho- 
genesis. Moreover, the paucity of some T cell cytokines 
and the contrasting abundance of monokines has led to 
the view that RA (at least in its late stages and perhaps 
in all stages) is a disease in which the key cellular 
elements are monocytes and synoviocytes. In this view, T 
cell responses may be an interesting but essentially 
unimportant by-product of synovial inflammation and 
destruction. 
In the present review, several aspects of the 
biology of the T cell in RA will be considered in the 
context of currently changing concepts about the patho- 
genesis of this disease. The focus will be primarily on 
studies of human disease rather than on animal models, 
and will emphasize recent observations. Consideration 
of these issues is not only of importance in understand- 
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Table 1. Evidence for the importance of T cells in RA* 
~ 
1. Abundance of T cells in synovial tissue and fluid. 
2. Selective accumulation in the joint of specific T cell subsets 
defined by differentiation and activation markers. 
3. Linkage of RA to specific class I1 MHC alleles. 
4. Important role of T cells in animal models of inflammatory 
5.  Improvement in RA with T cell-directed therapeutic approaches 
6. Presence of expanded oligoclonal T cell populations in RA (?). 




ing RA, but should also bear upon appropriate direc- 
tions for innovations in its therapy. 
The synovial T cell population: clonal or hetero- 
geneous? 
The association of RA with a class I1 MHC 
epitope implies that antigen-specific responses of CD4+ 
T cells are required for the development of this disease. 
If such clones could be identified in human RA, as they 
have been in various animal models, rational targeted 
approaches to immunotherapy would be possible. Ef- 
forts have therefore been directed at analysis of the T 
cell population in the lesion, with the goal of detecting T 
cell receptors (TCR) that are preferentially used in RA 
and that might identify antigen-specific clones important 
in the pathogenesis of the disease. Experimental ap- 
proaches used to tackle this question have included 
analysis of TCR gene rearrangements, detailed investi- 
gation of the repertoire of messenger RNA (mRNA) 
expression for the various T cell receptors, and direct 
immunologic analysis of receptor families expressed on 
the T cell surface. For the most part these studies have 
focused on the p chain rather than the a chain. Only a 
few of the dozens of studies in this area are cited in this 
review. 
Results of this work have thus far been notable 
for their contradictory and confusing nature. Earlier 
work that used Southern blot analysis to detect oligo- 
clonal populations led to disparate conclusions (2,3). 
Some of these discrepancies were reconciled by the 
subsequent finding that oligoclonality, when detected, is 
present only among synovial lymphocytes that respond 
to interleukin-2 (IL-2) and therefore must express high- 
affinity IL-2 receptors (4,5), a subset that includes only a 
small minority of synovial T cells (6). 
Many of the more recent studies of the RA TCR 
repertoire have used polymerase chain reaction (PCR) 
amplification of complementary DNA corresponding to 
TCR p chain (and in some studies, a chain) mRNA 
expressed by the entire T cell population in RA synovial 
fluid, tissue, or peripheral blood (for recent review, see 
ref. 7). This approach has allowed quantitative analysis 
of the level of expression of each Vp family. In some 
instances, sequencing has been performed on individual 
Vp transcripts. Several of these studies have suggested 
increased or decreased usage of particular Vp families, 
but the results have not been consistent among the 
different studies (8-15). Particularly striking results were 
obtained by Paliard et al, who found marked depletion 
of Vpl4-positive cells from peripheral blood, with 
readily detectable Vp14 expression in the synovial com- 
partment (16). Possible interpretations of such results 
include superantigen activation of this Vp family in the 
periphery, with either migration of activated cells into 
lesional tissues or death of such cells. Some other 
investigations have also shown increased usage of Vp14 
or the related Vp3 or Vp17 TCR families in synovial 
fluid or tissue (9,10,12,14), although the results have 
often been more subtle than those observed by Paliard 
and colleagues (8,10,12), have been confined to Vp3 
and/or Vp17 (14), or have been restricted to synovial 
fluid, not synovial tissue (12). Other studies have shown 
overrepresentation of different Va or Vp families, but 
not Vp3, Vp14, or Vp17, in RA synovial fluid (11,13,15). 
Thus far, analysis of the Vp repertoire expressed 
in the synovial compartment has not helped to implicate 
specific antigens in the etiology or pathogenesis of RA. 
However, the frequency of antigen-specific cells in 
antigen-driven lesions can be <1% of the total T cell 
infiltrate. Therefore, current data do not exclude the 
possibility of a critical role for antigen-specific clonal T 
cell responses in the initiation or progression of RA. 
An alternative approach to quantitating TCR 
V-region usage in RA, which avoids technical problems 
associated with PCR, is to determine the percent of T 
cells that express TCR subtypes by flow cytometry. 
Table 2. Evidence against the importance of T cells in RA* 
1. T cell responses to specific antigens have not been shown to 
2. Demonstration of oligoclonal T cells in RA has been difficult, 
3. T cell-derived cytokines are less abundant in the joint than are 
4. Erosion of cartilage and bone does not always correlate with 
trigger RA. 
and different oligoclonal populations appear in different patients. 
cytokines produced by other cell types. 
inflammation, and may become independent of regulation by T 
cells. 
therapeutic in RA. 
5. Depletion of T cells by monoclonal antibodies may not be 
* RA = rheumatoid arthritis. 
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Results of such studies have not been consistent thus far, 
with Va2 (17) or Vp17 (18) preferentially used by 
synovial fluid T cells, and skewed representations of 
various Vp receptor families among CD4+ or CD8+ T 
cells in synovial tissue (19). 
A more detailed and laborious approach to un- 
derstanding the RA T cell population involves sequenc- 
ing receptor gene segments utilized by individual T cells. 
The third complementarity-determining region (CDR3) 
of the TCR p chain, which includes the V-D-J junc- 
tions, interacts directly with peptide bound in the MHC 
groove, and has been the principal target of such analy- 
ses (for review, see ref. 7). Taken together, the results 
suggest that the T cell response in RA synovial fluid or 
tissue, although heterogeneous, is focused in a manner 
distinct from that in normal peripheral blood or RA 
peripheral blood, and is characterized by a tendency for 
certain amino acids, such as valine, to be used more 
frequently in the CDR3 (7,20,21). 
Although it has been proposed that skewed TCR 
usage in RA is confined to the joint, more recent studies 
suggest that the peripheral TCR repertoire may also be 
abnormal (22,23), in both the CD4+ (22,23) and CD8+ 
(24) subsets. However, a study of monozygotic twins 
discordant for RA revealed no differences in the peri- 
pheral Vp repertoire (25). If the TCR repertoire is 
indeed abnormal in RA, this could be due to effects of 
MHC alleles during T cell development (see below), 
selective outgrowth of a subset of T cell clones stimu- 
lated by as-yet-unidentified antigen(s) and/or superanti- 
gen(s), or immunologic perturbations that are a conse- 
quence of local and systemic inflammation. The 
possibility that unusual manipulations of the immune 
system produce TCR repertoire skewing is illustrated by 
the appearance of new oligoclonal T cell populations in 
both RA blood and synovium following monoclonal 
antibody depletion of T cells in vivo (26). Expansion of 
certain T cell subpopulations when RA synovial T cells 
are injected into joints of SCID mice could reflect a 
similar mechanism (27). 
Clonally expanded subsets of lymphocytes, 
present among RA B cells (28-30) as well as RA T cells, 
are not necessarily specific for self or foreign antigens 
important in disease pathogenesis. Instead, they may be 
markers for immunoregulatory disturbances that are 
nonspecific and that foster random outgrowth of various 
lymphocyte clones. A recent report suggests that defec- 
tive regulation of clonal T cell proliferation or survival is 
common in RA but not in psoriatic arthritis, is readily 
detectable in peripheral blood lymphocytes studied us- 
ing sensitive techniques, is present in unaffected family 
members of RA patients, and could be an inherited trait 
that is a risk factor for RA (31). 
It is also possible that intercurrent infections, 
subclinical or overt, may affect the lymphocyte reper- 
toire expressed in an autoimmune lesion, to a noticeable 
degree. Thus, T cells bearing TCR p chains that include 
a specific Vp segment, activated by microbial superan- 
tigens or nominal antigens at sites distant from the joint, 
may, during the course of activation, express augmented 
levels of various adhesion molecules. Such cells would 
then migrate through activated endothelium in inflamed 
synovium and accumulate in the joint. Nonspecific and 
cytokine-mediated activation mechanisms may be suffi- 
cient to cause such populations to persist for weeks or 
months in autoimmune lesions. Thus, the finding of 
common Vp expansions in patients followed up at one 
center during one period of time may be an “imprint” of 
pathogens epidemic in that community in the previous 
weeks or months. Other patient groups studied in geo- 
graphically distant areas or at different points in time 
would be expected to show different “imprints.” Such 
phenomena could be linked to periodic flares of disease, 
but may offer no clue to etiology and early pathogenesis. 
In this view, the RA synovium, as a result of chronic 
inflammation, becomes a lymphoid organ that reflects 
systemic immune responses. Appropriate control lym- 
phocyte populations for lymphocyte repertoire analysis 
might be found in lymph node or spleen, not peripheral 
blood. 
MHC alleles in RA: implications for the role of T cells 
The MHC gene cluster is understood in consid- 
erable detail, and the terminology used to describe its 
individual polymorphic genes and their protein products 
has changed in recent years. A recent review describes 
the current nomenclature for MHC alleles (32). Al- 
though specific MHC polymorphisms are risk factors for 
the development of a variety of human diseases, includ- 
ing RA, the mechanism(s) for such associations remains 
uncertain. Since the primary known function of class I1 
MHC is to present antigen to CD4+ T cells, it seems 
likely that the association of R A  with a specific class I1 
MHC sequence, termed “the shared epitope” (33), 
provides a clue to a role for T cells in the pathogenesis 
of RA. Recent work has even suggested that alternative 
amino acid residues at position 71 of DRBl correlate 
with clinical subsets of RA (34). Moreover, binding 
studies have identified distinctions between peptides 
that can be externally inserted into RA-associated cell 
surface D R  molecules compared with non-RA- 
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associated DR (35). Such distinctions include a limited 
number of peptides derived from the sequences of 
potential autoantigens such as type I1 collagen and the 
65-kd heat-shock protein (36). 
It would be premature, however, to deduce that 
the RA-associated DRBl epitope triggers disease by 
presenting an arthritogenic peptide to T cells. The 
repertoire of peptides displayed by each MHC allele can 
be investigated by isolating and sequencing the peptides 
directly, using homozygous cell lines. Unique peptides 
that are displayed selectively by RA-associated DRBl 
molecules have not been found with this approach, 
although peptides that are displayed only by non-RA- 
associated DRBl molecules have been identified (37). 
Recent studies also suggest that the presence of 2 copies 
of RA-associated DRBl epitopes confers greater risk of 
disease and augmented disease severity compared with 1 
epitope (38-41). Such findings provide evidence, al- 
though not conclusive, against presentation of an arthri- 
togenic antigen by DR, since this should operate in a 
strictly dominant manner. Alternatively, the “shared 
epitope” could augment risk for RA byfailing to present 
an antigen that the immune system must recognize in 
order to prevent RA. In this view, non-RA-associated 
DRBl alleles would be protective, and activation of T 
cells would be triggered by antigen(s) presented by 
non-DR MHC molecules, such as DP, DQ, and class I. 
A similar hypothesis has been formulated based on the 
findings that HLA-DQ8 confers susceptibility to 
collagen-induced arthritis in a transgenic mouse system 
and that alleles of the polymorphic H-2E locus (the 
murine homolog of HLA-DR) confer protection from 
disease (42). 
Other mechanisms proposed to explain the link- 
age of RA with the MHC have focused on the QKRAA 
amino acid sequence (or similar sequences) at positions 
70-74 of HLA-DRB1 alleles that are RA associated. 
Certain microbial antigens, including a bacterial heat- 
shock protein, also contain the QKRAA sequence, and 
are recognized by synovial fluid T cells from patients 
with early RA (42). Since peptides derived from MHC 
molecules can themselves be presented as antigens to T 
cells, it has been suggested that DRBl peptides contain- 
ing QKRAA can function as antigens that participate in 
positive selection of T lymphocytes in the thymus. Such 
cells would subsequently respond to microbial antigens 
with shared peptide sequences, and cross-react with 
putative autoantigens in the joint (43). 
Direct analysis of the TCR repertoire expressed 
by naive, CD4+ peripheral blood T cells has indeed 
indicated differences between individuals who possess 
Table 3. MHC and RA: possible mechanisms for a link* 
1. Specific binding of self-antigen. 
2. Creation of holes in the repertoire by inability to present specific 
3. Cross-reactivity between foreign antigen and MHC. 
4. Regulation of positive and negative selection of T cells. 
5. Altered mechanisms of MHC intracellular trafficking and peptide 
antigen to T cells. 
loading. 
* MHC = major histocompatibility complex; RA = rheumatoid 
arthritis. 
HLA-DRB1* 04 (an RA-associated allele) and control 
subjects who are B1*04 negative (44). Further differ- 
ences were found between B1*04-positive individuals 
with RA versus those without RA (44). Although these 
results were interpreted as being due to events occurring 
during thymic selection (44), alternative explanations 
are possible since the expressed TCR repertoire could 
be altered by post-thymic selection mechanisms. No link 
has yet been made between the specific capabilities of 
the RA TCR repertoire and responses to putative 
autoantigens that might be important in RA. Although 
one recent report suggests that an allelic polymorphism 
in the TCR p locus is linked to an independent genetic 
risk factor for RA that acts in synergy with HLA-DR4 
(45), the exact nature of this locus has not yet been 
specified. 
A novel explanation for the association of 
QKRAA-containing DR molecules with RA has re- 
cently been proposed (46). It was found that an endog- 
enous 73-kd heat-shock protein bound selectively to 
such DR molecules through the QKRAA motif (46). 
Such intracellular binding could alter loading or presen- 
tation of antigens, or impede surface expression of the 
DR molecules. A hypothesis to link such a phenomenon 
to RA has not yet been proposed, but could involve 
failure to present a protective antigen, as outlined above. 
Resolving the mechanism(s) by which MHC alleles 
affect the risk of developing RA (Table 3) should yield 
insight into the role of T cells in RA and perhaps provide 
clues to the etiology of the disease. 
Synovial T cells: subsets, surface markers, and 
activation pathways 
Synovial fluid and synovial tissue T cells differ 
from normal or RA peripheral blood T cells in the 
expression of specific surface markers. Differential ex- 
pression of CD45 isoforms has been one method of 
distinguishing “naive” from “memory” T cells, and 
CD45 isoforms characteristic of memory T cells are 
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expressed more extensively in the synovial compartment 
than in peripheral blood (47,48). The interpretation of 
CD45 isoform pattern expression is complex, because 
these isoforms are regulated both by differentiation of 
functional T cell subsets and by T cell activation. 
The TCRyIS TCR T cell subset, generally a small 
minority of the total T cell population, comprises 4-6% 
of RA synovial fluid T cells (49,50) and perhaps a higher 
proportion of synovial tissue T cells (51). Although the 
role of y/S T cells in RA is not yet understood, the range 
of antigens to which such cells can respond may provide 
an intriguing clue to a unique role in autoimmunity 
(52-55). Thus, recent findings have established that y/S 
T cells can recognize novel nonpeptide antigens (55), as 
well as typical peptide antigens, heat-shock proteins, and 
superantigens (52-54). Mechanisms of antigen presen- 
tation, receptor costimulation, and intracellular signal- 
ing may all have unique properties in y/S T cells (54-56). 
Subsets or clones of y/S T cells may be expanded in the 
synovial fluid of some RA patients (57,58), but the in 
vivo mechanisms responsible for this are not yet estab- 
lished. Animal studies have indicated that, depending 
upon the stage of disease, y/S cells may serve either a 
regulatory or a pathogenic role in models of inflamma- 
tory arthritis (59,60). It is not yet known whether this is 
also the case in human RA. 
A growing number of T cell membrane glycopro- 
teins, such as CD28, have been implicated as having 
roles in costimulating or regulating T cell activation. 
Synovial T cells can functionally express not only CD28, 
but also CD28 ligands (61-63). However, in some RA 
patients, an expanded subset of CD4+, CD28- cells has 
been identified in the peripheral blood, and, to some 
extent, in the joint (64). These cells respond in the 
autologous mixed lymphocyte reaction (i.e., are autore- 
active) (64), and their costimulatory receptors are not 
yet known. 
Another structure that can convey co-activating 
signals is CD6 (65),  which is expressed on most T cells 
and which may play an important role in T cell autore- 
activity (66). One CD6 ligand, termed ALCAM, has 
been identified (67), and indirect evidence for other 
CD6 ligands has been obtained (68). ALCAM is ex- 
pressed much more strongly by keratinocytes and syno- 
viocytes than on peripheral blood antigen-presenting 
cells (APC) (ref. 68 and Singer NS, Fox DA: unpub- 
lished data). 
A surface structure termed CD60, identified by a 
monoclonal antibody generated against an RA synovial 
T cell line (69), could also have a role in activation of 
synovial T cells. CD60 is expressed on a minority of 
peripheral blood T cells but on a majority of T cells in 
autoimmune lesions, in synovium or in skin (6,69,70), 
and on nonlymphoid cells with which T cells interact in 
thymus, skin, and synovium (6,70-72). Antibody to 
CD60 is mitogenic or comitogenic for T lymphocytes, 
including T cell clones derived from RA synovial fluid 
(69,70,72,73). Although the CD60 antigen appears to be 
a marker for T cells that accumulate in autoimmune 
lesions, the mechanism for this preferential expression is 
not clear, since CD60, unlike class I1 MHC, is not 
induced by activation of T cells (69,73). It is possible that 
CD60 contributes to homing of T cells to sites of 
inflammation, that cytokine-directed differentiation of T 
cells enhances CD60 expression (74), or that a ligand for 
CD60 is mitogenic for such T cells following their entry 
into synovium, therefore expanding this population se- 
lectively. T cell receptors for extracellular matrix mole- 
cules found in synovium may also play a role in costimu- 
lation of T cell proliferation (75). The importance of 
non-TCR activating pathways for T cells in RA is also 
emphasized by the suggestion that signal transduction 
through the TCR is defective in RA (76). 
Origin and fate of synovial T cells 
The extent to which activation of synovial T cells 
occurs prior to entry into synovium (in lymph nodes, 
gut-associated lymphoid tissue, spleen, circulation, or 
other systemic sites), during the process of transendo- 
thelial migration into inflamed synovial tissue, or follow- 
ing entry into the synovium is not yet known. Also 
unknown is the life span of a synovial T cell, and under 
what circumstances such cells undergo apoptosis. Apo- 
ptosis can be induced ex vivo in synovial fluid T cells 
through the CD95/Fas molecule, but has been difficult 
to detect in lymphocytes in synovial tissue sections (77). 
It seems likely that T cells can return from the synovium 
to the circulation, but this process is not yet well charac- 
terized. Within the joint, there appear to be subtle differ- 
ences in subset distribution between perivascular lymphoid 
aggregates, other areas of the synovium, and synovial 
fluid. Presumably, cells move from the lymphoid aggre- 
gates out into the remaining areas of synovial tissue, and 
then into synovial fluid. However, this sequence of 
events has not been well studied, and it is not known 
whether reverse migration of cells can also occur. 
The location of T cells may be relevant to their 
functional responses, since different types of APC are 
concentrated in different regions of the synovial tissue or 
in synovial fluid. Unique properties of APC subsets 
(monocytes, macrophages, B lymphocytes, dendritic 
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cells, fibroblasts, and other populations) likely include 
restricted expression of specific costimulatory molecules 
and distinct profiles of secreted cytokines, which to- 
gether would play a defining role in the resulting T cell 
functional program. Potential interaction with a broad 
range of APC is facilitated by T cell differentiation to 
the memory phenotype (78), characteristic of most RA 
synovial T cells. 
Critical to the influx of T cells and other inflam- 
matory cells into the joint is up-regulation, expression, 
and function of an array of leukocyte endothelial cell- 
cell interaction molecules, collectively termed adhesion 
molecules. The role of such structures in RA has re- 
cently been reviewed in detail (79). Molecules relevant 
to the migration and retention of T cells in synovium 
probably include integrins and their ligands, selectins 
and their ligands, CD44, and other structures. Although 
indirect evidence suggests that unique receptor-ligand 
interactions may direct lymphocytes into synovial tissue 
(SO), molecular identification of such synovium-specific 
structures has not yet been accomplished. However, 
quantitative differences in the relative expression of 
E-selectin and intercellular adhesion molecule type 1 
(ICAM-1) by RA synovial endothelium versus other 
vascular endothelial populations has been described 
(81). Animal model systems have proven useful for 
describing the sequence of up-regulation of adhesion 
receptors on lymphocytes and other leukocytes that 
migrate into synovium (82) and for demonstrating the 
feasibility of therapeutic interruption of migration of 
such cells into synovium using monoclonal antibodies or 
soluble ligands (83-85). 
Cell-cell interactions in RA synovium 
Distinct cell populations in synovium that can 
interact with T cells include type A (macrophage-like) 
synoviocytes, type B (fibroblastic) synoviocytes, den- 
dritic cells, monocytes derived from peripheral blood, 
and B lymphocytes. Comprehensive reviews of synovial 
dendritic cell (86) and fibroblast (87) function have 
recently appeared in Arthritis 6; Rheumatism. Recent 
data suggest that all of these cell types might serve as 
APC or accessory cells for T cell activation, including 
not only the “professional APC” that are bone marrow 
derived, but also the synovial fibroblasts (88-90). Exper- 
iments using T cell mitogens that do not require MHC 
identity between APC and T lymphocytes (superanti- 
gens or lectins) suggest that type B synoviocytes possess 
accessory cell function of a potency comparable with 
that of professional APC (89). 
The ranges of ligands for costimulatory T cell 
surface structures that are expressed by various synovial 
APC are distinct. For example, type B synoviocytes lack 
ligands for CD28, but do express ligands for CD2 and 
lymphocyte function-associated antigen 1 (LFA-1) that 
are important in superantigen-induced T cell activation 
(89). The LFA-1 molecule (CDlla/CDlS) on synovial 
fluid T cells is in a high avidity state, apparently induced 
by a factor present in synovial fluid (91), and it seems 
likely that synovial tissue T cells would also express an 
activated form of LFA-1. Superantigens can also trigger 
production of inflammatory mediators by synoviocytes, 
following up-regulation of the inducible isoform of 
cyclooxygenase, cyclooxygenase-2 (92). 
Type B synoviocytes and T cells can also interact 
in the absence of superantigen (89,93,94). A factor 
secreted by synoviocytes, not yet identified, promotes 
survival of activated T cells (93). Unactivated lympho- 
cytes can adhere to interferon-y (1FNy)-treated syno- 
viocytes (89,94), although less strikingly than in the 
presence of superantigen (89). Such adhesion is medi- 
ated by vascular cell adhesion molecule type 1 (CD106) 
and ICAM-1 (CD54), which are strongly expressed by 
synoviocytes (89,94). Glucocorticoids inhibit both ex- 
pression of these molecules and cell adhesion (94), 
suggesting one plausible mechanism for the therapeutic 
effects of intraarticular steroids, and possibly also sys- 
temic steroids. in RA. 
Production and utilization of cytokines by FL4 synovial 
T cells 
Cytokines play a dominant role in the pathophys- 
iology of joint inflammation and destruction in RA 
(95,96), and the results of recent studies suggest that 
interfering with the function of cytokines, particularly 
tumor necrosis factor, may be an effective approach to 
therapy both in rodent models and in human RA 
(97,98). Monocyte-derived cytokines contribute to acti- 
vation of T cells, other leukocytes, and endothelium, and 
to joint damage and remodeling, the latter through 
effects on synoviocytes and chondrocytes (99). 
The cytokine repertoire of synovial fluid and 
synovial tissue T cells is not well understood, and lack of 
high levels of IL-2 production in the synovial compart- 
ment has raised doubts about the role of T cells in RA 
(100). Whether Thl or Th2 cells predominate is contro- 
versial (101,102). In one study (103), synovial $8 cells 
were found to have different cytokine production pro- 
files than alp cells (less IFNy and IL-10, but more IL-4). 
The Thlmh2 model of distinct T cell cytokine profiles 
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may prove difficult to apply to diseases such as RA, since 
individual T cells can adapt more than one cytokine 
profile and production of individual cytokines can be 
independently regulated (104). 
Recent information about 3 cytokines found in 
RA synovium, IL-10, IL-15, and fibroblast growth factor 
1 (FGF-l), may help explain apparent paradoxes about 
the biology of F W  synovial T cells. IL-15 is a cytokine 
with a secondary structure (but not primary sequence) 
similar to that of IL-2. Like IL-2, it has T cell activating 
properties, and it uses a receptor complex that shares 2 
of its 3 subunits with the IL-2 receptor (105). Unlike 
IL-2, it is not produced by T cells, but instead from a 
variety of sources including fibroblasts and monocytes 
(106). Most significantly, it is abundant in the joint 
(unlike IL-2), and has a range of mitogenic and chemo- 
tactic activities that are likely important in influx and 
activation of T cells in synovium (106). 
A recent report also suggests that FGF-1 may be 
important in activation of RA synovial T cells (107). 
FGF-1 is abundant in the joint, and FGF-1 receptor- 
bearing T cells are common among CD4+ cells in 
perivascular infiltrates in RA synovium. Moreover, a 
higher proportion of peripheral blood T cells from RA 
patients was activated by FGF-1, compared with cells 
from normal subjects or patients with systemic lupus 
erythematosus. 
It is now believed that a major reason for the 
relative paucity of IL-2 in the RA joint is the production 
in synovium of IL-10, which suppresses synthesis of Thl  
cytokines. Elevated levels of IL-10 are found in RA 
synovial tissue, synovial fluid, and serum (108-110). 
IL-10 is likely produced by non-T cells in synovium and 
peripheral blood (108-110), and possibly also by syno- 
vial T cells, which, at a clonal level in vitro, can produce 
high levels of both IL-10 and IFNy (111). Evidence for 
antiinflammatory effects of IL-10 both in collagen- 
induced arthritis in mice (112) as well as in cell culture 
systems using RA synovial fluid mononuclear cells (1 13) 
has prompted consideration of the use of IL-10 as a 
novel therapeutic agent in RA. This would be based on 
the premise that the high levels of IL-10 in RA synovium 
are not quite sufficient to achieve its antiinflammatory 
effect. Our understanding of the biology of IL-10 is 
probably not yet sufficiently complete to predict its 
therapeutic potential in chronic RA. 
New directions in the treatment of RA. should T cells 
be the targets? 
Efforts to treat RA by depleting T cells using 
monoclonal antibodies or immunotoxins have generally 
been disappointing (1 14-119). Particularly problematic 
has been the lack of correlation between the biologic 
effects of such “high-tech” therapies (elimination of 
lymphocytes) and clinical responses. One potential ex- 
planation is insufficient depletion of synovial T cells to a 
level below the minimum threshold needed to sustain 
joint inflammation (120,121). In this regard, it is of 
interest that profound CD4 T cell lymphopenia, in the 
setting of the acquired immunodeficiency syndrome, 
does not necessarily suppress RA (122), contrary to 
previous impressions. Enumeration of CD4+ cells in 
synovia of such patients would be informative. 
Other T cell-directed approaches might target 
antigen-specific responses. Such strategies are based on 
the effectiveness of induction of tolerance to tissue- 
specific antigens, such as type I1 collagen, in animal 
model systems (123), or induction of immunoregulatory 
circuits using vaccination with specific TCR peptides 
(124). Transferring such strategies to genetically diverse 
humans with established disease involves many hurdles. 
A preliminary study of oral type I1 collagen in the 
treatment of RA appeared to show significant benefit in 
a subset of patients with established disease (125), but a 
subsequent larger study in patients with early RA 
showed only minimal benefit that was not statistically 
significant (126). Results of an ongoing multicenter trial 
should be available soon. Another novel approach in- 
volves infusion of allogeneic leukocytes, in an attempt to 
duplicate pregnancy-induced immunosuppression of RA 
(127). At this time, understanding of the biologic and 
clinical effects of this strategy is rudimentary, and much 
more information will be needed to evaluate its possible 
role in treating RA. 
If specific infectious agents can ultimately be 
identified as the cause of RA, therapy directed at the 
specific organisms and/or the immune responses to such 
organisms should be useful. Infection with human T 
lymphotropic virus type I (HTLV-I) has been shown to 
be associated with an RA-like syndrome in Japan 
(128,129). HTLV-I can infect synoviocytes as well as T 
cells (130), and can induce joint inflammation in rodents 
(131). However, in most RA patients, there is no con- 
vincing evidence linking the disease to retroviruses, 
mycoplasmas, or other pathogens. 
Conclusion 
The T cell-centered paradigm for RA, as it was 
formulated approximately 10 years ago, now seems 
outdated. In light of unimpressive levels of T cell 
cytokines in synovium and unimpressive clinical results 
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of therapeutic T cell depletion, reasonable arguments 
that depict the T cell as relatively unimportant in RA, 
especially in chronic disease, have been advanced. Con- 
currently, intensive analysis has failed to identify patho- 
genic antigen-driven T cell clones in the joint in human 
RA. However, increased understanding of two broad 
classes of molecules should now prompt development of 
a new model for the role of T cells in RA. 
The first class of molecules is the growing list of 
membrane structures that transmit costimulatory signals 
to the T cell, based on direct interaction with cell surface 
ligands on other cells-not only on dendritic cells, 
monocytes, and B cells, but also on parenchymal cells 
such as fibroblastic synoviocytes. The notion that syno- 
vial T cell responses in RA are driven by autoantigens 
presented to the immune system by the shared epitope 
needs to be reevaluated. Some recent data are more 
consistent with the notion of an indirect role for the 
shared epitope in RA and with a polyclonal T cell 
response in the joint triggered by antigens displayed by 
non-DR MHC molecules in conjunction with activation 
signals delivered by costimulatory ligands. 
The second class of molecules is the cytokines- 
the local and systemic hormones of immunity, inflam- 
mation, and host defenses. The number of known cyto- 
kines and their receptors has grown remarkably in the 
last decade. Recent information about the abundance 
and function of some of the newer cytokines in RA 
synovium, especially IL-10 and IL-15, may resolve ap- 
parent paradoxes about the role of T cells in RA and 
allow construction of a better-informed, more convinc- 
ing T cell paradigm. This paradigm should involve a 
sequence of pathologic cell-cell interactions in RA, 
which result in conversion of the synovium from an 
organ focused on maintaining local tissue homeostasis to 
an organ that becomes a component of the systemic 
lymphoid system, and eventually to a partially trans- 
formed, invasive, and destructive chronic inflammatory 
tissue. Future novel therapeutic approaches to RA that 
are specific, safe, and effective will disrupt one or more 
of the pathologic cell-cell interactions essential for this 
sequence of events, rather than directly eliminating one 
of the participating cell populations. 
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